for people ages 40-80 (full criteria)
at Medford, Oregon and other locations
study started



A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase 2a Study to Explore the Efficacy and Safety of Tezepelumab in Adults with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)

Official Title

A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multicenter Phase 2a Study to Explore the Efficacy and Safety of Tezepelumab in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) (COURSE)


This is a Phase 2a, multicenter, randomized, double-blind, placebo-controlled, parallel group study to evaluate the safety and efficacy of tezepelumab in adults with moderate to very severe chronic obstructive pulmonary disease (COPD) receiving triple inhaled maintenance therapy, and having had 2 or more documented COPD exacerbations in the 12 months prior to Visit 1. Approximately, 338 subjects will be randomized globally. Subjects will be stratified by region and prior number of exacerbations (2 vs. 3 or more). Subjects will receive tezepelumab, or placebo, administered via subcutaneous injection at the study site, over a 52 week treatment period. The study also includes a post-treatment follow-up period of 12 weeks.


Chronic Obstructive Pulmonary Disease (COPD), COPD, Moderate COPD, Severe COPD, chronic obstructive pulmonary disease, Lung Diseases, Obstructive Lung Diseases, Tezepelumab


You can join if…

Open to people ages 40-80

  1. History of moderate to very severe physician-diagnosed COPD for at least 12 months prior to enrolment with a post-bronchodilator FEV1/FVC<0.70 and a post-bronchodilator FEV1 ≥20% and ≤80% of predicted normal value.
  2. History of at least 2 documented moderate to severe COPD exacerbations within 2 to 52 weeks prior to enrollment.
  3. CAT score of ≥15 at enrollment and on day of randomization.
  4. Documented treatment with triple therapy for COPD (medium or high dose ICS/LABA/LAMA) throughout the year prior to enrollment. The dose of ICS should be stable for 3 months prior to enrollment.

You CAN'T join if...

  1. Clinically important pulmonary disease other than COPD, as judged by the Investigator (including current or historic asthma diagnosis).
  2. Any disorder, including, but not limited to, cardiovascular, gastrointestinal, hepatic, renal, neurological, musculoskeletal, infectious (including risk factors for pneumonia), endocrine, metabolic, hematological, psychiatric, or major physical impairment that is not stable.
  3. Major surgery within 8 weeks before enrollment.
  4. History of clinically significant infection requiring antibiotics or antiviral medication within 14 days before enrollment.
  5. Pregnant or breastfeeding.
  6. The chest/lungs with pathology that precludes the patient's ability to complete the study
  7. The patient has active COVID 19 infection during screening period.


  • Research Site
    Medford Oregon 97504 United States
  • Research Site
    Upland California 91786 United States


accepting new patients
Start Date
Completion Date
Sign up for this study
Phase 2 Chronic Obstructive Pulmonary Disease Research Study
Study Type
About 337 people participating
Last Updated